相似文献
1
The role of factor Xa inhibitors in venous thromboembolism treatment.
Vasc Health Risk Manag. 2015 Jan 30;11:117-23. doi: 10.2147/VHRM.S39726. eCollection 2015.
2
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
J Mal Vasc. 2014 May;39(3):183-94. doi: 10.1016/j.jmv.2014.02.001. Epub 2014 Mar 18.
3
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Expert Opin Pharmacother. 2015 Apr;16(5):645-58. doi: 10.1517/14656566.2015.999043. Epub 2015 Jan 2.
4
New oral anticoagulants for the treatment of venous thromboembolism.
Best Pract Res Clin Haematol. 2013 Jun;26(2):151-61. doi: 10.1016/j.beha.2013.07.005. Epub 2013 Jul 22.
5
Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
Expert Opin Drug Saf. 2019 Apr;18(4):313-320. doi: 10.1080/14740338.2019.1601699. Epub 2019 Apr 8.
6
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Eur J Vasc Endovasc Surg. 2014 Nov;48(5):565-75. doi: 10.1016/j.ejvs.2014.05.001. Epub 2014 Jun 18.
7
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Thromb Res. 2014 Oct;134(4):774-82. doi: 10.1016/j.thromres.2014.06.020. Epub 2014 Jul 6.
8
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Thromb Haemost. 2015 Feb;113(2):231-46. doi: 10.1160/TH14-06-0484. Epub 2014 Oct 16.
9
Re: 'Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Eur J Vasc Endovasc Surg. 2015 Mar;49(3):353. doi: 10.1016/j.ejvs.2014.11.019. Epub 2014 Dec 30.
10
Response to 'Re: Kakkos et al. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials'.
Eur J Vasc Endovasc Surg. 2015 Mar;49(3):353-4. doi: 10.1016/j.ejvs.2014.12.007. Epub 2014 Dec 30.
引用本文的文献
1
Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis.
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251372947. doi: 10.1177/10760296251372947. Epub 2025 Sep 5.
2
Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors.
J Thromb Thrombolysis. 2024 Dec;57(8):1308-1314. doi: 10.1007/s11239-024-03054-2. Epub 2024 Nov 1.
3
A mediastinal lesion with superior vena cava obstruction: A diagnostic and therapeutic challenge.
Lung India. 2024 Sep 1;41(5):382-384. doi: 10.4103/lungindia.lungindia_249_24. Epub 2024 Aug 31.
4
Lower Limb Deep Venous Thrombosis After Posterior Spinal Fusion as an Initial Manifestation of Factor V Leiden Mutation in a Pediatric Patient: A Case Report.
Cureus. 2024 Apr 3;16(4):e57543. doi: 10.7759/cureus.57543. eCollection 2024 Apr.
5
New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants.
ACS Omega. 2024 Feb 22;9(9):10694-10708. doi: 10.1021/acsomega.3c09335. eCollection 2024 Mar 5.
6
A retrospective study of adverse drug events in anticoagulant administration with relevance to COVID-19.
Heliyon. 2023 Mar;9(3):e13763. doi: 10.1016/j.heliyon.2023.e13763. Epub 2023 Feb 24.
7
Drug-drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case-control study in the National COVID Cohort Collaborative (N3C).
BMJ Open. 2022 Dec 29;12(12):e066846. doi: 10.1136/bmjopen-2022-066846.
8
Analysis of the Preventive Action of Rivaroxaban against Lower Extremity Deep Venous Thrombosis in Patients after Laparoscopic Radical Gastrectomy.
Comput Math Methods Med. 2022 Sep 10;2022:7140066. doi: 10.1155/2022/7140066. eCollection 2022.
9
A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia.
PeerJ. 2022 Sep 9;10:e13974. doi: 10.7717/peerj.13974. eCollection 2022.
10
Appropriateness of Prescribing Rivaroxaban at King Khalid University Hospital Riyadh.
Cureus. 2022 Jan 5;14(1):e20977. doi: 10.7759/cureus.20977. eCollection 2022 Jan.
本文引用的文献
1
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.
Clin Pharmacol Drug Dev. 2013 Oct;2(4):358-66. doi: 10.1002/cpdd.53. Epub 2013 Sep 9.
2
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Br J Clin Pharmacol. 2015 May;79(5):838-46. doi: 10.1111/bcp.12541.
3
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
J Thromb Thrombolysis. 2015 Feb;39(2):155-65. doi: 10.1007/s11239-014-1102-5.
4
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.
5
Oral apixaban for the treatment of acute venous thromboembolism.
N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.
6
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
Am J Cardiovasc Drugs. 2013 Oct;13(5):331-42. doi: 10.1007/s40256-013-0029-0.
7
Apixaban for extended treatment of venous thromboembolism.
N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.
8
Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
Drug Metab Dispos. 2012 Dec;40(12):2250-5. doi: 10.1124/dmd.112.046888. Epub 2012 Aug 30.
9
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.
Br J Clin Pharmacol. 2013 Feb;75(2):476-87. doi: 10.1111/j.1365-2125.2012.04369.x.
10
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.
Zotero 插件